In English | En español

National Cancer Institute

at the National Institutes of Health

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI

Clinical Trials Search Results

Page Options

Email This Document

Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat

Popular Resources

Help Using the NCI Clinical Trials Search Form
Learn About Clinical Trials
About NCI's List of Cancer Clinical Trials
NCI Dictionary of Cancer Terms
NCI Drug Dictionary

View Content for:

Patients
Health Professionals

Display:

Title
Description with: Locations Eligibility
Full Trial Description
Custom

Results 1-25 of 172 for your search:

Drug:  melphalan
Find trials that include:  Any drugs shown
Trial Status:  Active

Hide Search Criteria

Show Search Criteria

Help with Results

Select All on Page Sort by: Show Results per Page

Phase III/IV Randomized Study of Risk-Adapted Therapy Comprising Observation Only, Combination Chemotherapy, Radiotherapy, and/or Autologous Stem Cell Transplantation in Younger Patients With Neuroblastoma

Phase: Phase IV, Phase III
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: GPOH-NB2004, EU-20661, NCT00410631

Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple Myeloma

Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: UARK 2003-26, NCT00090493

Stem Cell Transplantation for Hematological Malignancies

Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 35 and under
Sponsor: Other
Protocol IDs: 2000LS040, MT2000-12, 0005M52481, UMN-2000LS040, NCT00176839

Phase II/III Randomized Study of Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: UHW-AML16, EU-20677, ISRCTN11036523, EUDRACT-2005-002846-14, MREC-CU106, NCT00454480

Randomized Study of Velcade-based Regimen With Autologous Stem Cell Transplantation in Newly-diagnosed Myeloma Patients

Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: MMY3024, NCT00984828

Autologous Transplant for Multiple Myeloma

Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: 2004LS001, MT2003-13, 0312M54569, UMN-2004LS001, UMN-MT2003-13, UMN-0312M54569, NCT00293306, NCT00177047

Safety and Efficacy Study of High Dose Melphalan HCL for Injection (Propylene Glycol-Free) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation

Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Approved-not yet active
Age: Any Age
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: CDX-353-002, NCT01660633

Phase III Randomized Study of Sequential Chemotherapy With or Without Rituximab Followed By Ablative Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation in Patients With Relapsed, CD20 Positive, Aggressive B-Cell Non-Hodgkin's Lymphoma

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: CKTO-2000-06, HOVON-44, HOVON-44/CKVO-2000-06, EU-20042, ISRCTN95614846, NCT00012051

Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma

Phase: Phase III
Type: Treatment
Status: Active
Age: Under 50
Sponsor: NCI, Other
Protocol IDs: CDR0000068608, EURO-EWING-INTERGROUP-EE99, EBMT-INTERGROUP-EE99, EORTC-62981, GPOH-AUSTRIA-INTERGROUP-EE99, GPOH-GERMANY-INTERGROUP-EE99, SFOP-INTERGROUP-EE99, SWS-SAKK-INTERGROUP-EE99, CCLG-INTERGROUP-EE99, COG-AEWS0331, EU-20213, AEWS0331, NCT00020566

10.

Combination Chemotherapy With or Without Filgrastim Before Surgery, High-Dose Chemotherapy, and Radiation Therapy Followed by Isotretinoin With or Without Monoclonal Antibody in Treating Patients With Neuroblastoma

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 20 at diagnosis
Sponsor: Other
Protocol IDs: CDR0000069191, SIOP-EUROPE-HR-NBL-1, ESIOP, EU-20148, NCT00030719

11.

Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: MCL2004-2, NCT00209222

12.

Combination Chemotherapy in Treating Young Patients With Hodgkin's Lymphoma

Phase: Phase III
Type: Diagnostic, Treatment
Status: Active
Age: 17 and under
Sponsor: Other
Protocol IDs: CDR0000531687, EURONET-PHL-C1, EU-20703, EUDRACT-2006-000995-33, CCLG-HD-2007-10, NCT00433459

13.

Zevalin and BEAM High-dose Chemotherapy Compared With BEAM Alone as Conditioning Regimen in Patients With Chemosensitive Relapse of Non-Hodgkin's Lymphoma

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: Sor451107ctil, NCT00463463

14.

Zevalin-beam for Aggressive Lymphoma

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: SHEBA-07-4466-AN-CTIL, NCT00491491

15.

Multi Centre Trial of DSMM for Newly Diagnosed Multiple Myeloma up to 60 Years

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 60
Sponsor: Other
Protocol IDs: DSMM V, NCT00546988

16.

Efficacy and Safety of Aprepitant in Subjects With Multiple Myeloma During and After High-dose Chemotherapy

Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: EmNa (2001-004956-38), EudraCT-No: 2004-004956-38, NCT00571168

17.

UARK 2008-01, Total Therapy 4 - A Phase III Trial for Low Risk Myeloma

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: UARK 2008-01, NCT00734877

18.

Phase III Randomized Study of High-Dose Melphalan and Second Autologous Stem Cell Transplantation Versus Low-Dose Cyclophosphamide in Patients With Relapsed Multiple Myeloma After Re-induction Chemotherapy

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: LCC-HM05/7287, HM05/7287, EU-20873, ISRCTN60123120, EudraCT-2006-005890-24, NCT00747877

19.

Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: CDR0000633503, GOELAMS-LH2007, GOELAMS-ID-RCB#2007-A01079-44, INCA-RECF0754, AMGEN-GOELAMS-LH2007, NCT00920153

20.

Single Autologous Stem Cell Transplantation Followed by Maintenance Therapy as Front-line Treatment for Myeloma

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: MHOPES-myeloma09, NCT00892346

21.

Melphalan+Prednisolon With or Without Thalidomide in Previously Untreated Elderly Patients With Multiple Myeloma

Phase: Phase III
Type: Treatment
Status: Active
Age: 55 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: TMSG-2005-001, NCT00934154

22.

Study Comparing Isolated Pelvic Perfusion With TNF-a 0.3 mg and Melphalan 1.5 mg/kg Versus Standard Treatment in Patients With Non Resectable, Recurrent Gynaecologic or Digestive Pelvic Cancer

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 76
Sponsor: Other
Protocol IDs: PIP2, CSET 1443, NCT00949039

23.

Study in Localized and Disseminated Ewing Sarcoma

Phase: Phase III
Type: Treatment
Status: Active
Age: 4 to 50
Sponsor: Other
Protocol IDs: 108128, EudraCT number: 2008-003658-13, NCT00987636

24.

Phase III Randomized Study of Standard Induction Chemotherapy With or Without Nelarabine or Rituximab in Patients With Newly Diagnosed, Previously Untreated Acute Lymphoblastic Leukemia

Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 25 to 65
Sponsor: Other
Protocol IDs: UCL-08-0167, UCL/08/0167, EU-21009, EUDRACT-2009-012717-22, UCL-UKALL14, MREC-09-H0711-90, NCRI-UCL-08-0167, CRUK-C27995-A9609, NCT01085617

25.

The Combination of Lenalidomide and Dexamethasone With or Without Intensification by High-dose Melphalan in the Treatment of Multiple Myeloma